keyword
MENU ▼
Read by QxMD icon Read
search

PCDAI

keyword
https://www.readbyqxmd.com/read/29151253/a-two-week-fecal-microbiota-transplantation-course-in-pediatric-patients-with-inflammatory-bowel-disease
#1
Katarzyna Karolewska-Bochenek, Pawel Grzesiowski, Aleksandra Banaszkiewicz, Agnieszka Gawronska, Maria Kotowska, Marcin Dziekiewicz, Piotr Albrecht, Andrzej Radzikowski, Izabella Lazowska-Przeorek
Dysbiosis plays a major role in the etiology of inflammatory bowel disease (IBD). Fecal microbiota transplantation (FMT) is a new promising option for IBD treatment. We aimed to assess the effectiveness of a two-week FMT course in children with IBD. Ten patients, 10-17 years of age with moderate to severe IBD received a course of eight doses of freshly prepared FMT via a naso-duodenal tube or gastroscopy. All of the patients had pancolitis. There were eight cases of ulcerative colitis (UC) and two of Crohn's disease (CD)...
November 19, 2017: Advances in Experimental Medicine and Biology
https://www.readbyqxmd.com/read/28928769/exclusive-enteral-nutrition-versus-infliximab-in-inducing-therapy-of-pediatric-crohn-s-disease
#2
Youyou Luo, Jindan Yu, Jingan Lou, Youhong Fang, Jie Chen
AIM: To compare the effectiveness of exclusive enteral nutrition (EEN) and infliximab (IFX) therapy in pediatric Crohn's disease (CD). METHODS: In a prospective study of children initiating EEN or infliximab therapy for CD, we compared clinical outcomes using the pediatric Crohn's disease activity index (PCDAI), growth improvement, endoscopic mucosal healing, and adverse effects. Data were measured at baseline and after 8 weeks of therapy. RESULTS: We enrolled 26 children with CD; of whom, 13 were treated with infliximab, 13 with EEN...
2017: Gastroenterology Research and Practice
https://www.readbyqxmd.com/read/28906316/secondary-loss-of-response-to-infliximab-in-pediatric-crohn-s-disease-does-it-matter-how-and-when-we-start
#3
Rishi Bolia, Jeremy Rosenbaum, Vered Schildkraut, Winita Hardikar, Mark Oliver, Donald Cameron, George Alex
OBJECTIVES: A significant proportion of children with Crohn's disease develop a secondary loss of response (LOR) to infliximab. Our aim was to study the impact of initial treatment strategies on secondary LOR. METHODS: We reviewed the medical records of children with Crohn's disease who received scheduled maintenance infliximab therapy for at least 12 months. We compared children who developed LOR with those who did not; with regards to their clinical and laboratory parameters, disease phenotype and treatment strategy before developing LOR...
September 12, 2017: Journal of Pediatric Gastroenterology and Nutrition
https://www.readbyqxmd.com/read/28753181/real-life-anti-tumour-necrosis-factor-experience-in-500-paediatric-united-kingdom-inflammatory-bowel-disease-patients
#4
Victoria M Merrick, Kajal Mortier, Linda J Williams, Rafeeq Muhammed, Marcus Kh Auth, Mamoun Elawad, John Me Fell, R Mark Beattie, Sabarinathan Loganathan, Franco Torrente, Mary-Anne Morris, Charles Charlton, Nick M Croft, Astor Rodrigues, Mark Furman, Babu Vadamalayan, Huw Jenkins, Veena Zamvar, Sally G Mitton, Sonny Chong, Mike Cosgrove, Anthony Akobeng, David C Wilson, Richard K Russell
OBJECTIVES: To measure the effectiveness, safety and use of anti-Tumour necrosis Factor (TNF) therapy in paediatric inflammatory bowel disease (PIBD) in the United Kingdom (UK). METHODS: Prospective UK audit of patients newly starting anti-TNF therapy. Disease severity was assessed using Physician Global Assessment (PGA) +/or the Paediatric Crohn's Disease Activity Index (PCDAI). RESULTS: 37 centres participated (23 of 25 specialist PIBD sites)...
July 27, 2017: Journal of Pediatric Gastroenterology and Nutrition
https://www.readbyqxmd.com/read/28719106/altered-pulmonary-gas-transfer-capacity-and-capillary-blood-volume-in-pediatric-crohn-s-disease
#5
Marie Verstraete, Marie-Luce Choukroun, Valerie Siao-Him Fa, Michael Fayon, Laurent Rebouissoux, Raphael Enaud, Thierry Lamireau
OBJECTIVES: To describe diffusing capacity for carbon monoxide (DLCO) and its components, that is, membrane diffusing capacity (DmCO) and pulmonary capillary blood volume (Vc) in children with Crohn's disease (CD), and to investigate the correlation between these parameters and disease activity. WORKING HYPOTHESIS: The most common lung function abnormalities are a reduced pulmonary DLCO and small airways disorders which are in many instances, clinically silent. No valid explanations have been proposed regarding the modifications in gas transfer capacity in active CD...
August 2017: Pediatric Pulmonology
https://www.readbyqxmd.com/read/28575325/exclusive-enteral-nutrition-therapy-in-pediatric-crohn-s-disease-results-in-long-term-avoidance-of-corticosteroids-results-of-a-propensity-score-matched-cohort-analysis
#6
Jessica Connors, Sana Basseri, Amy Grant, Nick Giffin, Gamal Mahdi, Angela Noble, Mohsin Rashid, Anthony Otley, Johan Van Limbergen
Background & Aims: Exclusive enteral nutrition (EEN) is recommended as first-line induction therapy for pediatric Crohn's disease (CD) although corticosteroids (CS) are still used commonly. Our aim was to compare short- and long-term disease outcomes of pediatric CD patients initially managed with either EEN or CS. Methods: Medical records of newly-diagnosed pediatric CD patients treated with EEN or CS as induction therapy were retrospectively reviewed. To minimize selection bias inherent in observational cohort studies, propensity analysis was carried out...
May 27, 2017: Journal of Crohn's & Colitis
https://www.readbyqxmd.com/read/28420280/enteric-coated-budesonide-for-the-induction-and-maintenance-of-remission-of-crohn-s-disease-in-children
#7
Stanley A Cohen, Marina Aloi, Ramalingam Arumugam, Robert Baker, Kevin Bax, Jaroslaw Kierkuś, Sibylle Koletzko, Paolo Lionetti, Tore Persson, Stefan Eklund
OBJECTIVE: These studies evaluated the safety and efficacy of enteric-coated budesonide for the induction and maintenance of remission of mild-to-moderate Crohn's disease (CD) in children. METHODS: The consecutive, multicenter, open-label, non-comparative studies enrolled patients aged 6-17 years. In the induction study, patients with active CD of the ileum and/or ascending colon received budesonide 9 mg or 6 mg once daily for 8 weeks; in the maintenance study, patients in remission received budesonide 6 mg once daily for 12 weeks...
April 19, 2017: Current Medical Research and Opinion
https://www.readbyqxmd.com/read/28397432/evaluation-of-the-infliximab-therapy-of-severe-form-of-pediatric-crohn-s-disease-in-poland-retrospective-multicenter-studies
#8
MULTICENTER STUDY
Barbara M Iwańczak, Józef Ryżko, Piotr Jankowski, Małgorzata Sładek, Agata Wasilewska, Mariusz Szczepanik, Edyta Sienkiewicz, Anna Szaflarska-Popławska, Sabina Więcek, Grażyna Czaja-Bulsa, Bartosz Korczowski, Jolanta Maślana, Franciszek Iwańczak, Magdalena Kacperska
BACKGROUND: Registration of infliximab in Poland has increased chances to induce clinical remission and mucosal healing in the severe form of pediatric Crohn's disease. OBJECTIVES: The aim of this retrospective study was to assess the results and safety of infliximab therapy in the severe form of pediatric Crohn's disease. MATERIAL AND METHODS: The study included 153 children with severe form of non-fistulizing Crohn's disease treated with infliximab...
January 2017: Advances in Clinical and Experimental Medicine: Official Organ Wroclaw Medical University
https://www.readbyqxmd.com/read/28337236/adalimumab-for-endoscopic-and-histopathological-mucosal-healing-in-paediatric-patients-with-moderate-to-severe-crohn-s-disease
#9
Edyta Szymanska, Maciej Dadalski, Wieslawa Grajkowska, Sylwia Szymanska, Maciej Pronicki, Jaroslaw Kierkus
INTRODUCTION: Deep remission, defined as clinical remission with mucosal healing (MH), with anti-tumor necrosis factor (TNF)-α agents is a new target for therapy in Crohn's disease (CD). Provided that the efficacy of infliximab (IFX) for induction of MH in CD has been demonstrated, there are much less data for adalimumab (ADA), and none concerning MH on histopathological examination. AIM: To assess the impact of biological therapy with ADA on both endoscopic and histopathological MH in paediatric patients with CD...
2017: Przegla̜d Gastroenterologiczny
https://www.readbyqxmd.com/read/28216137/low-predictive-value-of-histopathological-scoring-system-for-complications-development-in-children-with-crohn-s-disease
#10
Ondrej Fabian, Ondrej Hradsky, Kristyna Potuznikova, Alena Kalfusova, Lenka Krskova, Ludmila Hornofova, Josef Zamecnik, Jiri Bronsky
OBJECTIVES: In pediatric Crohn's disease (PCD), the benefit of microscopy in disease activity assessment and prediction of clinical outcome is, due to the focality and transmurality of the inflammation, disputable. We investigated whether histopathological scoring system predicts complications in pediatric CD and correlates with endoscopical and clinical scores. METHODS: We performed a retrospective study on 63 patients. Endoscopy in the time of diagnosis was evaluated using the Simple Endoscopic Score (SES) and histopathology with the Global Histology Activity Score, both in its original version (GHAS) and its modification (modGHAS)...
April 2017: Pathology, Research and Practice
https://www.readbyqxmd.com/read/28169974/f-calprotectin-and-blood-markers-correlate-to-quality-of-life-in-pediatric-inflammatory-bowel-disease
#11
Katrine Carlsen, Christian Jakobsen, Thomas Kallemose, Anders Paerregaard, Lene B Riis, Pia Munkholm, Vibeke Wewer
OBJECTIVES: Our aim was to investigate predictors of health-related quality of life (HRQoL) with respect to changes in disease parameters over time in children with inflammatory bowel disease. METHODS: This was a prospective longitudinal study examining the association between HRQoL (IMPACT III) and symptom scores (Pediatric Crohn Disease Activity Index, abbreviated Pediatric Ulcerative Colitis Activity Index), fecal calprotectin measures and blood analyses (C-reactive protein, erythrocyte sedimentation rate, orosomucoid, albumin, hemoglobin, and vitamin-D) in a cohort of 10- to 17-year-old patients with inflammatory bowel disease...
November 2017: Journal of Pediatric Gastroenterology and Nutrition
https://www.readbyqxmd.com/read/28125551/o-003-the-brain-as-extraintestinal-ibd-manifestation-are-brain-and-cognitive-differences-in-pediatric-crohn-s-disease-associated-with-immune-gene-expression
#12
Christine Mrakotsky, Dunn W Augustine, Christopher Watson, James Canavan, Michael Rivkin, Scott Snapper
BACKGROUND: Structural brain changes in gray and white matter have been previously found in adults with Crohn's disease (CD). We have recently shown similar effects for pediatric CD in 2 separate studies (Mrakotsky et al., 2012, 2013, 2015), particularly for cortical and subcortical brain regions important for cognition, memory and emotion. Our prior data also revealed serum markers of inflammation and steroid therapy to be negatively associated with cortical thickness, subcortical volume, cognitive and school function, however, associations between brain structure and more detailed inflammatory profiles have not been studied...
February 2017: Inflammatory Bowel Diseases
https://www.readbyqxmd.com/read/28030510/clinical-and-fecal-microbial-changes-with-diet-therapy-in-active-inflammatory-bowel-disease
#13
David L Suskind, Stanley A Cohen, Mitchell J Brittnacher, Ghassan Wahbeh, Dale Lee, Michele L Shaffer, Kimberly Braly, Hillary S Hayden, Jani Klein, Benjamin Gold, Matthew Giefer, Angela Stallworth, Samuel I Miller
GOAL: To determine the effect of the specific carbohydrate diet (SCD) on active inflammatory bowel disease (IBD). BACKGROUND: IBD is a chronic idiopathic inflammatory intestinal disorder associated with fecal dysbiosis. Diet is a potential therapeutic option for IBD based on the hypothesis that changing the fecal dysbiosis could decrease intestinal inflammation. STUDY: Pediatric patients with mild to moderate IBD defined by pediatric Crohn's disease activity index (PCDAI 10-45) or pediatric ulcerative colitis activity index (PUCAI 10-65) were enrolled into a prospective study of the SCD...
December 27, 2016: Journal of Clinical Gastroenterology
https://www.readbyqxmd.com/read/27759462/peripheral-and-intestinal-t-regulatory-cells-are-upregulated-in-children-with-inflammatory-bowel-disease-at-onset-of-disease
#14
Katarzyna Sznurkowska, Anton Żawrocki, Jacek Sznurkowski, Maciej Zieliński, Piotr Landowski, Katarzyna Plata-Nazar, Ewa Iżycka-Świeszewska, Piotr Trzonkowski, Agnieszka Szlagatys-Sidorkiewicz, Barbara Kamińska
BACKGROUND/AIMS: To determine the proportion of T-regulatory cells (CD4(+)CD25(high)FOXP3(+) cells) in peripheral blood and the number of FOXP3(+) cells in intestinal mucosa of children with inflammatory bowel disease (IBD), and to verify whether these parameters correlate with the activity of the disease. MATERIAL AND METHODS: 24 patients newly diagnosed for IBD were included in the study: ulcerative colitis (UC; n = 13) and Crohn's disease (CD; n = 11). Seventeen healthy controls (HC) and 16 patients with irritable bowel syndrome (IBS) served as a control group for peripheral and intestinal Tregs assessment, respectively...
October 19, 2016: Immunological Investigations
https://www.readbyqxmd.com/read/27713779/the-impact-of-induction-therapy-with-three-doses-of-infliximab-on-deep-histological-healing-in-paediatric-patients-with-active-crohn-s-disease
#15
Edyta Szymanska, Maciej Dadalski, Sylwia Szymanska, Wieslawa Grajkowska, Maciej Pronicki, Jaroslaw Kierkus
INTRODUCTION: The clinical efficacy of infliximab (IFX) for induction of remission in both adults and children with active Crohn's disease (CD) has been well documented. Recently, so-called "deep remission" defined as mucosal healing has become the ultimate endpoint of the most recent therapeutic advances for CD. However, endoscopic evidence of mucosal healing is not necessarily associated with histological evidence of suppression of inflammation. AIM: Since data on that issue are limited, especially in the paediatric population, the aim of this study was to assess the impact of induction therapy with IFX on deep microscopic remission in paediatric patients with CD...
2016: Przegla̜d Gastroenterologiczny
https://www.readbyqxmd.com/read/27602705/text-messaging-effect-on-adherence-in-children-with-inflammatory-bowel-disease
#16
Tamir Miloh, Mitchell Shub, Ramon Montes, Kristy Ingebo, Gary Silber, Brad Pasternak
BACKGROUND: Successful treatment of patients with inflammatory bowel disease (IBD) requires regular intake of medication. Nonadherence to treatment is associated with increased frequency of relapses, morbidity, and cost. METHODS: Pediatric patients with IBD taking oral medication and with access to text messaging (TM) services were included. Children were randomized by age, sex, medication administration responsibility (self vs parent), and disease activity (Pediatric Crohn Disease Activity Index or Pediatric Ulcerative Colitis Activity Index) into TM intervention and standard of care...
June 2017: Journal of Pediatric Gastroenterology and Nutrition
https://www.readbyqxmd.com/read/27576956/pediatric-crohn-s-disease-iron-deficiency-anemia-and-intravenous-iron-treatment-a-follow-up-study
#17
Sara Valério de Azevedo, Catarina Maltez, Ana Isabel Lopes
BACKGROUND AND AIMS: Increasing evidence in adults demonstrates efficacy and safety of IV iron in inflammatory Bowel disease (IBD) associated iron deficiency anemia; however, evidence in pediatric patients is yet scarce and no previous study has included a long follow-up. This study aimed to evaluate safety and efficacy of IV iron (primary end point), and the need of re-treatment (secondary end point), in this setting. METHODS: Prospective recruitment (40 months); PCDAI determined before and after treatment; anemia defined according to WHO criteria; IV iron treatment included iron sucrose and ferric carboxymaltose...
January 2017: Scandinavian Journal of Gastroenterology
https://www.readbyqxmd.com/read/27429426/tacrolimus-exerts-only-a-transient-effectiveness-in-refractory-pediatric-crohn-disease-a-case-series
#18
Oriane Truffinet, Christine Martinez-Vinson, Emilie Guerriero, Jean-Pierre Hugot, Jérôme Viala
OBJECTIVES: Tacrolimus is an immunosuppressive agent that has been proposed in the treatment of severe ulcerative colitis. The present study examined the effectiveness and safety of tacrolimus in treating refractory Crohn disease (CD) colitis in children. METHODS: All children treated by oral tacrolimus for CD colitis at a tertiary pediatric center were included in the study. All patients were refractory to steroids and infliximab. Clinical response (decreased pediatric CD activity index [PCDAI] >15 and PCDAI <30) and remission (PCDAI <10) were monitored at 2, 4, 6, 12, and 24 months after induction...
May 2017: Journal of Pediatric Gastroenterology and Nutrition
https://www.readbyqxmd.com/read/27277259/assessing-pediatric-ileocolonic-crohn-s-disease-activity-based-on-global-mr-enterography-scores
#19
Fabio Pomerri, Faise Al Bunni, Monica Zuliani, Graziella Guariso, Marco Gasparetto, Benedetta Giorgi, Mara Cananzi, Pier Carlo Muzzio
OBJECTIVES: This study was aimed at correlating a magnetic resonance index of activity (MaRIA) and a magnetic resonance enterography global score (MEGS) with activity indexes in a paediatric population with Crohn's disease (CD). METHODS: This retrospective study included 32 paediatric patients (median age 14.5 years, 18 male) with proven CD who underwent magnetic resonance enterography (MRE). A correlation analysis was performed on the MRE-based scores, the simplified endoscopic score for CD (SES-CD), the paediatric Crohn's disease activity index (PCDAI), and C-reactive protein (CRP) levels...
March 2017: European Radiology
https://www.readbyqxmd.com/read/27110920/the-prevalence-of-irritable-bowel-syndrome-type-symptoms-in-paediatric-inflammatory-bowel-disease-and-the-relationship-with-biochemical-markers-of-disease-activity
#20
K Diederen, D R Hoekman, T Z Hummel, T G de Meij, B G P Koot, M M Tabbers, A M Vlieger, A Kindermann, M A Benninga
BACKGROUND: A large proportion (25-46%) of adults with inflammatory bowel disease in remission has symptoms of irritable bowel syndrome (IBS), which are thought to reflect ongoing inflammation. Data on paediatric inflammatory bowel disease patients are lacking. AIM: To investigate (i) the prevalence of IBS-type symptoms in paediatric inflammatory bowel disease patients in remission and (ii) the relationship of IBS-type symptoms with biochemical markers of disease activity...
July 2016: Alimentary Pharmacology & Therapeutics
keyword
keyword
34104
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"